Hematopathology [recurso electrónico] : Genomic Mechanisms of Neoplastic Diseases / edited by Domnita Crisan.
Tipo de material: TextoSeries Molecular and Translational MedicineEditor: Totowa, NJ : Humana Press : Imprint: Humana Press, 2011Descripción: XII, 360 p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9781607612629Tema(s): Medicine | Hematology | Oncology | Pathology | Medicine & Public Health | Pathology | Hematology | Molecular Medicine | OncologyFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 616.07 Clasificación LoC:RB1-214Recursos en línea: Libro electrónicoTipo de ítem | Biblioteca actual | Colección | Signatura | Copia número | Estado | Fecha de vencimiento | Código de barras |
---|---|---|---|---|---|---|---|
Libro Electrónico | Biblioteca Electrónica | Colección de Libros Electrónicos | RB1 -214 (Browse shelf(Abre debajo)) | 1 | No para préstamo | 372582-2001 |
Chapter 1: Molecular techniques used in Hematopathology -- Chapter 2: Cytogenetics techniques used in Hematopathology -- Chapter 3: The molecular component of the new WHO classification of hematologic malignancies -- Chapter 4: Molecular pathology of pediatric acute leukemias -- Chapter 5: Molecular pathology of adult acute leukemias -- Chapter 6: Molecular pathology of lymphomas -- Chapter 7: Molecular pathology of chronic myeloproliferative neoplasms -- Chapter 8: Molecular pathology of CLL -- Chapter 9: Targeted therapy in hematologic malignancies -- Chapter 10: MicroRNAs in hematologic malignancies.
Hematopathology: Genomic Mechanisms of Neoplastic Diseases will keep physicians abreast of the rapid and complex changes in genomic medicine, as exemplified by the molecular pathology of hematologic malignancies. This timely volume will update physicians on the complexities of genomic lesions, as well as offer an integrated framework encompassing molecular diagnosis, the new WHO classification of hematologic neoplasms with focus on molecular pathology, prognostic value of molecular tests, and molecular monitoring of response to gene-targeted therapy. As such, it will be of great value to hematologists, oncologists, pathologists, internal medicine and pediatric specialists, as well as bioscientific staff and laboratorians in private hospitals and academic institutions.
19